Hjem › Kronisk lymfatisk leukæmi › Connecticut
Kronisk lymfatisk leukæmi kliniske forsøg i Connecticut
4 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i Connecticut.
Byer i Connecticut
Officiel studietekst (engelsk)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Yale University Yale Cancer Center, New Haven
- Eastern Connecticut Hematology and Oncology, Norwich
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06943872A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Eastern CT Hematology & Oncology Associates ( Site 0033), Norwich
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06136559A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Yale Cancer Center, New Haven
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Yale University School of Medicine /ID# 266224, New Haven
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. apr. 2026 · NCT06428019Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.